Decreasing the Unplanned Readmission Rate of Patients receiving Outpatient Antibiotic Therapy(OPAT)

Dr. Jose Cadena Dr. Amruta Parekh

University of Texas Health Science Center at San Antonio San Antonio, TX



CONTACT

Jose Cadena, M.D. (210) 567-1871 cadenazuluag@uthscsa.edu



TEAM

- PHYSICIANS
 Chief / Medical Service Jan Patterson, MD
 Infectious Disease Fellow Jose Cadena, MD
- FACILITATOR
 Amruta Parekh, MD, MPH
- NURSING Irene Cataldo, R.N. Theresa Gore, RN.
- PHARMACY Kelly Echeverria PharmD
- •TECH/STATISTICAL SUPPORT Wayne Fischer, MS, PhD







LIST OF CUSTOMERS

- PATIENTS
- PROVIDERS
- NURSING
- PHARMACY
- HOSPITAL ADMINISTRATION



AIM STATEMENT

To decrease the unplanned readmission rate of patients receiving outpatient antibiotic therapy (OPAT) due to infection, line complications or adverse drug reactions by 30% by December 2008 at ALMVA hospital.




What was the VA working with?


 We retrospectively evaluated the failures among patients receiving OPAT at the ALMVA over a 3 month period.

Rate of Adequate Follow up	32%
Rate of readmission	44%
	(54% of which within 2 weeks)
Rate of Central Line Complication	12%
Rate of Antibiotic Complications(rash, C	36%
difficile associated disease-CDAD, failure)	
Patients alive at end of therapy	84%
Patients with microbiological diagnosis	68%

PROCESS FLOW - Pre Intervention



CAUSE & EFFECT DIAGRAM



BACKGROUND

- Outpatient Antibiotic Therapy (OPAT) is an alternative to inpatient care.
 It is safe and effective when used properly.
- Proper assessment of the patients required: OPAT indication, social situation and comorbidities
- Ordering physician: Should be **aware** of the team work, communication, monitoring and outcome measurements!
- Patient should be informed of his responsibilities and plan to follow up.
- Antibiotics: Proper choice, dosing and monitoring. Initiated in hospital or clinic.



PERTINENT POINTS FROM LITERATURE

- OPAT is a complex process. A Healthcare
 Failure Mode Effect Analysis has shown that
 OPAT may have 6 processes, 67 sub-processes
 and 217 possible failures.
- Our project was a first step to standardize and improve the process.



Mandatory ID consultation for OPAT

 Infectious diseases consultation results in change in management of 88.6% patients considered candidates for OPAT

 Mandatory ID consultation decreases cost by \$760 per patient.

High success rate of therapy (97%)

But remember.....


 OPAT may have 6 processes, 67 subprocesses and 217 possible failures.

Gilchrist M et al. J Antimicrob Chemotherapy 2008; 62: 177-83.


How

- Infectious Disease Physician and ID PharmD:
 - Review cases to make sure that therapy is appropriate
 - Ensure ID clinic follow up when appropriate
 - Address complications in the clinic
 - Review the patient to make sure they are able to care for themselves.
 - Discuss with team and patient goals and responsibilities of therapy.
- Constant communication between MD, Pharm D, RN and home health.

Preintervention data of readmissions during treatment





PROCESS FLOW - Post Intervention



Postintervention data of readmissions during treatment

102.8





Rate of completion of parental therapy

	Preintervention	Postintervention
Total Number	47	37
Completed Treatment	26 (55%)	30 (81%)
Did not complete	21 (45%)	7 (19%)

p = 0.04

Postintervention rate of completion of parental therapy was better

Complications Requiring Readmissions

	Pre intervention N: 47	Post intervention N: 37
CHF/Volume overload	3	0
ARF, electrolyte disturbance	3	0
PICC line Infection/removal	4 (2/2)	0
Amputations	4	1
Worsening Infection	8	1
SJS/Severe rash/toxicity	2	1
All-Cause Mortality	2	2
Total	17 (36%)	4 (13%)

Number of patients with serious complications requiring readmission reduced in the post intervention period

Complications (overall)

	N:47	N:37
Acute Renal Failure	3 (6%)	2 (5%)
Congestive Heart Failure	3 (6%)	0
PICC problems	4 (9%)	2 (5%)
Amputations	4 (9%)	1 (3%)
Unrelated readmissions	6 (12%)	5 (14%)
Worsening Infection	8 (17%)	1 (3%)
SJS/Severe rash/toxicity	2 (4%)	1 (3%)
All-Cause Mortality	2 (4%)	2 (5%)
Total	32	14

Follow up and readmissions

	Pre intervention	Post intervention	P value
Follow up at 7 days (labs)*	21/39 (54%)	21/36 (62%)	0.7
Follow up within 2 weeks (MD) *	22/36 (61%)	26/35 (74%)	0.2
Readmitted during treatment	15/47 (32%)	5/37 (14%)	0.049
Readmitted within 3 months	20/47 (43%)	8/37 (22%)	0.043

^{*}Denominator: eligible patients.

RETURN ON INVESTMENT

	% Patients Readmitted	Admissions / Month*	Average LOS
Pre intervention	43%	3.2	14 days
Post intervention	22%	1.7	

Cost - Physician FTE (2/8)	(\$43,849)
Potential Admissions Avoided / Yr	18
Potential Admission Days Avoided / Yr**	252
Cost Savings (if only regular bed days avoided – would be higher for higher level of care)	\$428,400
Cost savings – cost physician	\$384,551
Return on investment	89%



^{*}Assume 90 patients per year


^{**} Hospital day cost 1700\$

WHERE ARE WE GOING?

Program was transiently discontinued pending resolution of funding issues.

There was a proposal to create a position for an ID physician to supervise the process and was submitted to the hospital directives

April 2009: Approved position. Recruitment completed. Plan to restart program in July 2009.





CONCLUSIONS

- ID physician direction
 - Decreased complications and readmission
 - Cost-effective and cost-saving
 - Improved quality and patient safety
- Most complications could be managed as outpatient
- Process was initially labor intensive but rewarding
- •Further improvement is required for patients with less prolonged hospital stay.



QUESTIONS?





